Purpose: To examine the progression pattern of myopic maculopathy.
Design: Retrospective, observational case series.
Participants: Highly myopic patients who had been followed up for 10 years or more.
Methods: Using fundus photographs, myopic features were differentiated according to Meta-analysis of Pathologic Myopia (META-PM) Study Group recommendations.
Main Outcome Measures: Progression pattern of maculopathy.
Results: The study included 810 eyes of 432 patients (mean age, 42.3±16.8 years; mean axial length, 28.8±1.9 mm; mean follow-up, 18.7±7.1 years). The progression rate of myopic maculopathy was 47.0 per 1000 eye-years. Within the pathologic myopia (PM) group (n = 521 eyes), progression of myopic maculopathy was associated with female gender (odds ratio [OR], 2.21; P = 0.001), older age (OR, 1.03; P = 0.002), longer axial length (OR, 1.20; P = 0.007), greater axial elongation (OR, 1.45; P = 0.005), and development of parapapillary atrophy (PPA; OR, 3.14; P < 0.001). Diffuse atrophy, found in 217 eyes without choroidal neovascularization (CNV) or lacquer cracks (LCs) at baseline, progressed in 111 (51%) eyes, leading to macular diffuse atrophy (n = 64; 64/111 or 58%), patchy atrophy (n = 59; 53%), myopic CNV (n = 18; 16%), LCs (n = 9; 5%), and patchy-related macular atrophy (n = 3; 3%). Patchy atrophy, detected in 63 eyes without CNV or LCs at baseline, showed progression in 60 eyes (95%), leading to enlargement of original patchy atrophy (n = 59; 59/60 or 98%), new patchy atrophy (n = 29; 48%), CNV-related macular atrophy (n = 13; 22%), and patchy-related macular atrophy (n = 5; 8%). Of 66 eyes with LCs, 43 eyes (65%) showed progression with development of new patchy atrophy (n = 38; 38/43 or 88%) and new LCs (n = 7; 16%). Reduction in best-corrected visual acuity (BCVA) was associated mainly (all P < 0.001) with the development of CNV or CNV-related macular atrophy and enlargement of macular atrophy.
Conclusions: The most frequent progression patterns were an extension of peripapillary diffuse atrophy to macular diffuse atrophy in diffuse atrophy, enlargement of the original atrophic lesion in patchy atrophy, and development of patchy atrophy in LCs. Main risk factors for progression were older age, longer axial length, and development of PPA.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.ophtha.2017.12.005 | DOI Listing |
Am J Ophthalmol
December 2024
Department of Ophthalmology, New Civil Hospital, Strasbourg University Hospital, FMTS, Strasbourg, France. Electronic address:
Purpose: To describe a new feature in pathologic myopia: perivascular patchy chorioretinal atrophy (PVCA) DESIGN: Cross-sectional study METHODS: 604 eyes of 312 highly myopic patients followed at Strasbourg University Hospitals were reviewed for the presence of PVCA lesions. Demographic, clinical, and paraclinical data (ultra-widefield retinography, optical coherence tomography (OCT), fluorescein and indocyanine green angiography images) were analyzed. Controls were matched for age, sex, and axial length (AL).
View Article and Find Full Text PDFOphthalmol Sci
September 2024
Rothschild Foundation Hospital, Institut Français de Myopie, Paris, France.
Purpose: To examine intraretinally migrated retinal pigment epithelium cells (iRPECs) in enucleated human eyes with various retinal conditions and corresponding intraretinal hyperreflective bodies (iHRBs) in a large cohort of patients with age-related macular degeneration (AMD) in China.
Design: Population-based study and histomorphometric investigation.
Participants: Participants of the population-based Beijing Eye Study and enucleated human eyes.
Pediatr Dermatol
December 2024
Department of Dermatology, Medical University of Warsaw, Warsaw, Poland.
Background: Lichen planopilaris (LPP) is the most common form of scarring alopecia in adults. The disease may also occur in children and adolescents. The aim of this systematic review is to evaluate clinical, trichoscopic, and histopathologic features of pediatric LPP.
View Article and Find Full Text PDFAsia Pac J Ophthalmol (Phila)
December 2024
Department of Ophthalmology, Faculty of Medicine, University of Cologne, University Hospital Cologne, Cologne, Germany.
Cells
October 2024
Department of Ophthalmology and Visual Sciences, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
There are currently no effective treatments for retinal pigment epithelial (RPE) cell loss in atrophic AMD (aAMD). However, our research on (), a known structural protein in photoreceptors (PRs), has revealed its distinct role in RPE and offers promising insights. While pathogenic mutations have been linked to macular diseases with RPE atrophy, the broader physiological impact of dysfunctional in RPE loss is unclear.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!